Evaluation of the first 50 ACR360 acrylic intraocular lens implantations.
To evaluate the clinical results of implantation of the ACR360 soft acrylic intraocular lens (IOL). Civico Hospital, Lugano, Switzerland. This prospective, medium-term study comprised the first 50 consecutive patients who had small incision scleral tunnel phacoemulsification and implantation of an ACR360 acrylic IOL (loptex/Allergan). Intraoperative and postoperative complications, best corrected visual acuity (BCVA), intraocular pressure (IOP), preoperative and postoperative astigmatism, and IOL centration were recorded. Mean follow-up was 12 months +/- 3 (SD). One day postoperatively, 94% of best cases (n = 46) achieved a BCVA of 20/40 or better and 54%, 20/25 or better. At 2 weeks, 98% had 20/40 or better and 78%, 20/25 or better. After 6 months, all patients achieved a BCVA of 20/40 or better and 83%, 20/25 or better. No statistically significant changes in keratometric astigmatism or IOP occurred. The ACR360 IOL gave clinical results comparable to those of other foldable lenses; however, it can also be implanted in cases of intraoperative capsular complications and in eyes with intravitreal silicone oil. Development of an injecting system for implantation and substituting the polypropylene loops with poly(methyl methacrylate) haptics could improve lens quality.